With a new $300,000 Phase I SBIR grant from the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases, biotech startup Milo Biotechnology will march forward with development and testing of its follistatin therapy for muscular dystrophy. Its lead candidate, AAV1-FS344, is a gene therapy intended to up-regulate follistatin, a protein that blocks myostatin, […]
An experimental drug being developed by Milo Biotechnology for the treatment of certain neuromuscular diseases has been given orphan drug designation by the U.S. Food and Drug Administration. The Cleveland company’s drug candidate, AAV1-FS344, is a gene delivery therapy that’s designed to produce follistatin, a protein associated with muscle size and strength, in patients with […]
Scheduling software is helpful for wellness business owners in numerous ways. They get everything they need to create appointments, reschedule clients and track cancellations in one platform.
A clinical-stage biotechnology startup that’s developing a therapy for neuromuscular diseases such as muscular dystrophy has received a $250,000 investment from nonprofit economic development group JumpStart. Cleveland-based Milo Biotechnology’s drug candidate is based on technology developed at Columbus’ Nationwide Children’s Hospital, and the company has already begun a clinical trial there, according to a statement […]